Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants

OBJECTIVES: The study aimed to compare the immunogenicity and safety of fractional (half) third doses of heterologous COVID-19 vaccines (AZD1222 or BNT162b2) to full doses after the two-dose CoronaVac and when boosting after three different extended intervals. METHODS: At 60-<90, 90-<120, or 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Niyomnaitham, Suvimol, Jongkaewwattana, Anan, Meesing, Atibordee, Pinpathomrat, Nawamin, Nanthapisal, Sira, Hirankarn, Nattiya, Siwamogsatham, Sarawut, Kirdlarp, Suppachok, Chaiwarith, Romanee, Lawpoolsri, Saranath, Phanthanawiboon, Supranee, Thitithanyanont, Arunee, Hansasuta, Pokrath, Chaiyaroj, Sansanee, Pitisuttithum, Punnee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867652/
https://www.ncbi.nlm.nih.gov/pubmed/36682680
http://dx.doi.org/10.1016/j.ijid.2023.01.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867652/
https://www.ncbi.nlm.nih.gov/pubmed/36682680
http://dx.doi.org/10.1016/j.ijid.2023.01.022

Ejemplares similares